

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

GUIDANCE EXECUTIVE (GE)

Consideration of consultation responses on review proposal

Review of TA218; Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia

This guidance was issued March 2011 with a review date of February 2014.

Background

At the GE meeting of 11 February 2014 it was agreed we would consult on the review plans for this guidance. A four week consultation has been conducted with consultees and commentators and the responses are presented below.

Proposal put to consultees:	The guidance should be transferred to the 'static guidance list'.
Rationale for selecting this proposal	No new evidence has been identified that is likely to lead to a change in the recommendations of the original guidance. We therefore propose that this guidance is placed on the 'static list'.

GE is asked to consider the original proposal in the light of the comments received from consultees and commentators, together with any responses from the appraisal team. It is asked to agree on the final course of action for the review.

Recommendation post consultation:	The guidance should be transferred to the 'static guidance list'.
--	---

Respondent	Response to proposal	Details¹	Comment from Technology Appraisals
NHS Coventry and Rugby CCG	Agree	<p>We approve the move of TA218 to the static list on the basis that no new evidence has become available that would result in a change to the recommendations.</p> <p>However we need to be assured that should evidence become available that may lead to a change in the current recommendations then the TA is reviewed as soon as possible thereafter.</p>	Comments noted. Guidance placed on the 'static guidance list' remains in place and can be considered for review at any point if NICE becomes aware of substantive information which could lead to a change to the recommendations.
Royal College of Physicians	No objection	The RCP has no objection to the proposal that TA218 should be moved to the static list	Comment noted.
Royal College of Nursing	No comment	The Royal College of Nursing have no comments to submit to inform on the review proposal.	Comment noted.

¹ Comments received in the course of consultations carried out by NICE are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that NICE has received, and are not endorsed by NICE, its officers or advisory committees.

Respondent	Response to proposal	Details ¹	Comment from Technology Appraisals
MDS UK Patient Support Group	Agree	<p>MDS UK Patient Support Group has no further evidence to submit regarding azacitidine and also recommends this TA is moved to the static list.</p> <p>This medication has been proving extremely helpful to the relevant group of MDS patients, with many of them gaining many more months, or even years of survival, and experiencing a significant improvement to their Quality of Life, thanks to the treatment.</p> <p>MDS UK is also pleased to note that the PAS is working well and providing a substantial saving to the NHS.</p> <p>We encourage the use of PAS whenever possible and hope future MDS treatments will benefit from similar schemes to make drugs more accessible to MDS patients in the UK.</p>	Comments noted.

No response received from:

<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Celgene (azacitidine) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Afiya Trust • African Caribbean Leukaemia Trust 	<p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Commissioning Support Appraisals Service
--	--

- Anthony Nolan
- Aplastic Anaemia Trust
- Black Health Agency
- Cancer Black Care
- Cancer Equality
- Cancer52
- CML Support Group
- Equalities National Council
- Helen Rollason Cancer Charity
- Independent Cancer Patients Voice
- Leukaemia Cancer Society
- Leukaemia CARE
- Macmillan Cancer Support
- Maggie's Centres
- Marie Curie Cancer Care
- Muslim Council of Britain
- Muslim Health Network
- Rarer Cancers Foundation
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Tenovus

Professional groups

- Association of Cancer Physicians
- British Committee for Standards in Haematology
- British Geriatrics Society
- British Psychosocial Oncology Society
- British Society for Haematology
- Cancer Network Pharmacists Forum
- Cancer Research UK

- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare Products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Alliance
- NHS Commercial Medicines Unit
- NHS Confederation
- Scottish Medicines Consortium

Comparator manufacturers

- None

Relevant research groups

- Cochrane Haematological Malignancies Group
- Elimination of Leukaemia Fund
- Health Research Authority
- Institute of Cancer Research
- Leukaemia & Lymphoma Research
- Leukaemia Busters
- MRC Clinical Trials Unit
- National Cancer Research Institute
- National Cancer Research Network
- National Institute for Health Research
- Research Institute for the Care of Older People

Assessment Group

- Assessment Group tbc
- National Institute for Health Research Health Technology

<ul style="list-style-type: none"> • Royal College of General Practitioners • Royal College of Pathologists • Royal Pharmaceutical Society • Royal Society of Medicine • UK Health Forum • United Kingdom Clinical Pharmacy Association • United Kingdom Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS England • NHS Leeds North CCG • Welsh Government 	<p>Assessment Programme</p> <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Collaborating Centre for Cancer <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales NHS Trust
--	---

GE paper sign-off: Elisabeth George, Associate Director – Technology Appraisals Programme

Contributors to this paper:

Technical Lead: Chris Chesters

Project Manager: Andrew Kenyon

01 04 14